ReviewmAbs
Antibody immunosuppressive therapy in solid-organ transplant: Part I.
Review in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Trial
- Translating Antiviral Therapies to Veterinary Use: A Review of Immunomodulatory Agents for Potential Application in Aleutian Mink Diseases.Animals : an open access journal from MDPI · 2025Review
- Immunosuppressants/Immunomodulators and Malignancy.Journal of clinical medicine · 2025Review
- Structure, function, and immunomodulation of the CD8 co-receptor.Frontiers in immunology · 2024Review
- Evaluating Kaposi Sarcoma in Kidney Transplant Patients: A Systematic Review and Meta-Analysis.Cureus · 2024Review
- A Comprehensive Landscape ofTransplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Novel Immunosuppression in Solid Organ Transplantation.Handbook of experimental pharmacology · 2022Article
- TriTECM: A tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome.Frontiers in immunology · 2022Article
- The effect of immunosuppressive therapy after liver transplantation on activities of daily living and fear of death during the COVID-19 pandemic.Transplant immunology · 2021Article
- Osteopontin and Transplantation: Where Are We Now?Archivum immunologiae et therapiae experimentalis · 2021Review
- Drug delivery nanosystems targeted to hepatic ischemia and reperfusion injury.Drug delivery and translational research · 2021Review
- Immunosuppression trends in solid organ transplantation: The future of individualization, monitoring, and management.Pharmacotherapy · 2021Review
- Encephalopathy in a kidney transplant recipient.BMJ case reports · 2019Article
- Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries.BioMed research international · 2019Article
- Regulation of human T cell responses by dNP2-ctCTLA-4 inhibits human skin and microvessel graft rejection.Biomaterials · 2018Article
- Cyclophosphamide for Refractory Acute Cellular Rejection After Lung Transplantation.Transplantation direct · 2018Article
- Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells.JCI insight · 2017Article
- Evaluation of Immunosuppressive Therapy Use for Tracheal Transplantation with Trachea-Mimetic Bellows Scaffolds in a Rabbit Model.BioMed research international · 2017Article
- Use of nonhuman primates for the development of bioengineered female reproductive organs.Tissue engineering and regenerative medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, a wide variety of both polyclonal and monoclonal antibodies are being routinely utilized to prevent and treat solid organ rejection. More commonly, these agents are also administered in order to delay introduction of calcineurin inhibitors, especially in patients with already compromised renal function. While these antibody therapies dramatically reduced the incidence of acute rejection episodes and improved both short and long-term graft survival, they are also associated with an increased incidence of opportunistic infections and neoplastic complications. Therefore, effective patient management must necessarily balance these risks against the potential benefits of the therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.